Michael Cloonan Sells 7,793 Shares of Sionna Therapeutics (NASDAQ:SION) Stock

Sionna Therapeutics, Inc. (NASDAQ:SION) CEO Michael Cloonan sold 7,793 shares of the stock in a transaction on Monday, September 29th. The stock was sold at an average price of $29.70, for a total transaction of $231,452.10. Following the sale, the chief executive officer directly owned 547,343 shares in the company, valued at $16,256,087.10. This trade represents a 1.40% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Michael Cloonan also recently made the following trade(s):

• On Friday, September 26th, Michael Cloonan sold 17,207 shares of Sionna Therapeutics stock. The stock was sold at an average price of $28.85, for a total transaction of $496,421.95.
• On Tuesday, August 26th, Michael Cloonan sold 17,574 shares of Sionna Therapeutics stock. The shares were sold at an average price of $24.96, for a total transaction of $438,647.04.
• On Wednesday, August 27th, Michael Cloonan sold 7,426 shares of Sionna Therapeutics stock. The shares were sold at an average price of $25.01, for a total transaction of $185,724.26.

Sionna Therapeutics Stock Down 3.2%

SION opened at $28.47 on Thursday. Sionna Therapeutics, Inc. has a 52-week low of $7.26 and a 52-week high of $30.60. The firm’s fifty day simple moving average is $22.64 and its two-hundred day simple moving average is $17.09.

Sionna Therapeutics (NASDAQ:SION) last posted its quarterly earnings data on Monday, August 11th. The company reported ($0.41) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.68) by $0.27.

Hedge Funds Weigh In On Sionna Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the business. BNP Paribas Financial Markets purchased a new position in shares of Sionna Therapeutics in the second quarter worth about $31,000. Police & Firemen s Retirement System of New Jersey purchased a new position in Sionna Therapeutics during the second quarter worth about $45,000. Virtus Investment Advisers LLC purchased a new position in Sionna Therapeutics during the second quarter worth about $96,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in Sionna Therapeutics during the second quarter worth about $117,000. Finally, New York State Common Retirement Fund purchased a new position in Sionna Therapeutics during the second quarter worth about $118,000.

Analyst Ratings Changes

SION has been the topic of several recent analyst reports. Wall Street Zen raised shares of Sionna Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 16th. Jones Trading initiated coverage on shares of Sionna Therapeutics in a report on Monday, September 8th. They set a “buy” rating and a $46.00 price objective on the stock. Raymond James Financial initiated coverage on shares of Sionna Therapeutics in a research note on Tuesday, September 2nd. They issued a “strong-buy” rating and a $45.00 price target on the stock. Finally, Royal Bank Of Canada initiated coverage on shares of Sionna Therapeutics in a research note on Wednesday, September 3rd. They issued a “sector perform” rating and a $22.00 price target on the stock. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $38.00.

Sionna Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to CF patients.